Transposable Element Profiling for TDP-43 Neurodegenerative Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack specificity and effectiveness in treating, diagnosing, and assessing neurodegenerative disorders associated with TAR DNA-binding protein 43 (TDP-43), particularly in profiling transposable element (TE) expression levels, which are over-expressed in these disorders.
Innovation Solution
Developing methods to measure TE expression levels in biological samples, using transposon inhibitors to reduce expression, and employing techniques like MULTI and UNIQ+SameEle mapping to profile TE expression, thereby diagnosing and treating TDP-43 associated neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to diagnose neurodegenerative disorders, then the diagnosis can be made, but the methods lack specificity and effectiveness
Solution Approach 1:
The patent changes the diagnostic parameter from conventional markers to transposable element expression levels. By measuring TE expression (e.g., L1, Alu, SINEs) in biological samples, the method achieves both high specificity for TDP-43 associated disorders and effective diagnosis, resolving the contradiction between reliability and measurement precision.
2Measurement precision
If transposable element expression is measured to diagnose TDP-43 associated disorders, then diagnostic specificity improves, but the complexity of the measurement process increases
Solution Approach 1:
The patent employs universal mapping techniques (MULTI and UNIQ+SameEle mapping) that can profile multiple transposable element classes (LTR retrotransposons, non-LTR retrotransposons, SINEs) using a single integrated approach. This multi-functional method achieves high specificity while managing complexity through standardized profiling procedures.
3Reliability
If transposon inhibitors are administered to reduce transposable element expression, then treatment effectiveness improves, but the difficulty of detecting and measuring treatment response increases
Solution Approach 1:
The patent establishes a feedback mechanism where transposable element expression levels are measured before and after transposon inhibitor administration. By monitoring changes in TE expression (e.g., reduction in L1, Alu, or SINE transcripts), the method enables effective treatment while providing clear measurable response criteria, resolving the contradiction between treatment effectiveness and measurement difficulty.
Data Source
AI summary
A method that includes measuring the expression level of at least one transposon in a biological sample from a subject; and determining whether the measured transposon expression exceeds a predetermined level, and if so, administering to the subject a transposon inhibitor in an amount effective to reduce the expression level of a transposon.